This database contains 193 studies, archived under the term: "results"
Click here to filter this large number of results.
Trazodone improves sleep parameters in Alzheimer disease patients: A randomized, double-blind, and placebo-controlled study
Camargos, Einstein F.,
Louzada, Luciana L.,
Quintas, Juliana L.,
Naves, Janeth O.S.,
Louzada, Fernando M.,
Nóbrega, Otávio T.
Objectives: There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD). We tested the efficacy and safety of trazodone to treat SD in patients with AD. Design: We conducted a double-blind, randomized and controlled trial during periods of 7–9 days at baseline […]
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, Aaron H,
Grimes, Imogene,
Galasko, Douglas R,
Aisen, Paul S,
Sabbagh, Marwan,
Mjalli, Adnan MM
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]
Olive oil and cognition: results from the three-city study
Berr, Claudine,
Portet, Florence,
Carrière, Isabelle,
Akbaraly, Tasnime N.,
Feart, Catherine,
Gourlet, Véronique,
Combe, Nicole,
Barberger-Gateau, Pascale,
Ritchie, Karen
Background: Olive oil is a major component of the Mediterranean diet suggested to be beneficial to counteract Alzheimer’s disease.; Aim Of the Study: Our objective was to examine the association between olive oil use, cognitive deficit and cognitive decline in a large elderly population.; Methods: We followed 6,947 subjects with a brief baseline food frequency […]
Predicting decline in mild cognitive impairment: A prospective cognitive study
Objective: The primary aim of this study was to identify cognitive tests that differentiate between persons with mild cognitive impairment (MCI) who later develop cognitive decline and those who remain stable. Method: This study used a prospective longitudinal design. One hundred twenty-two older adults with single-domain or multiple-domain amnestic MCI were recruited from memory clinics. […]
A pilot study of the effects of internet-based cognitive stimulation on neuropsychological function in HIV disease
Becker, James T.,
Dew, Mary Amanda,
Aizenstein, Howard J.,
Lopez, Oscar L.,
Morrow, Lisa,
Saxton, Judith,
Tárraga, Lluís
Purpose: Mild cognitive deficits associated with HIV disease can affect activities of daily living, so interventions that reduce them may have a long-term effect on quality of life. We evaluated the feasibility of a cognitive stimulation program (CSP) to improve neuropsychological test performance in HIV disease.; Methods: Sixty volunteers (30 HIV-infected) participated. The primary outcome […]